Mollah Farhana, Varamini Pegah
Faculty of Medicine and Health, School of Pharmacy, University of Sydney, Sydney, NSW 2006, Australia.
Sydney Nano Institute, University of Sydney, Sydney, NSW 2006, Australia.
Biomedicines. 2021 Dec 15;9(12):1921. doi: 10.3390/biomedicines9121921.
Breast cancer is the most diagnosed cancer and is the leading cause of cancer mortality in women. Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer. Often, TNBC is not effectively treated due to the lack of specificity of conventional therapies and results in relapse and metastasis. Breast cancer-associated fibroblasts (BCAFs) are the predominant cells that reside in the tumor microenvironment (TME) and regulate tumorigenesis, progression and metastasis, and therapy resistance. BCAFs secrete a wide range of factors, including growth factors, chemokines, and cytokines, some of which have been proved to lead to a poor prognosis and clinical outcomes. This TME component has been emerging as a promising target due to its crucial role in cancer progression and chemotherapy resistance. A number of therapeutic candidates are designed to effectively target BCAFs with a focus on their tumor-promoting properties and tumor immune response. This review explores various agents targeting BCAFs in TNBC, including small molecules, nucleic acid-based agents, antibodies, proteins, and finally, nanoparticles.
乳腺癌是诊断最多的癌症，也是女性癌症死亡的主要原因。三阴性乳腺癌（TNBC）是一种侵袭性乳腺癌。通常，由于传统疗法缺乏特异性，TNBC无法得到有效治疗，从而导致复发和转移。乳腺癌相关成纤维细胞（BCAFs）是肿瘤微环境（TME）中的主要细胞，可调节肿瘤发生、进展、转移和治疗耐药性。BCAFs分泌多种因子，包括生长因子、趋化因子和细胞因子，其中一些已被证明会导致预后不良和临床结果不佳。由于该肿瘤微环境成分在癌症进展和化疗耐药性中起关键作用，它已成为一个有前景的靶点。许多治疗候选物旨在有效靶向BCAFs，重点关注其促进肿瘤的特性和肿瘤免疫反应。本综述探讨了TNBC中靶向BCAFs的各种药物，包括小分子、核酸类药物、抗体、蛋白质，最后是纳米颗粒。
